Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA

References

• Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis 1998;8(Suppl. 5):8-18.
   Google Scholar
• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary preven- tion of stroke. J Neurol Sci 1996;143:1–13.
   Google Scholar
• Algra A,.van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197–9.
   PubMed Web of Science ®Google Scholar
• Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733–44.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996;87:4925–36.
   PubMed Web of Science ®Google Scholar
• Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345–50.
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230–5.
   PubMed Web of Science ®Google Scholar
• Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331–6.
   PubMed Web of Science ®Google Scholar
• Chyatte D, Chen TL. Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease. Neurosurgery 1990;26:565–9.
   PubMed Web of Science ®Google Scholar
• Bornstein NM, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of aspirin treatment after stroke. Stroke 1994;25:275–7.
   PubMed Web of Science ®Google Scholar
• Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21(Suppl. 2):12–.
   Google Scholar
• Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999;10:25–31.
   PubMed Web of Science ®Google Scholar
• Kundu S, Sio R, Mitu A, and Ostgaard R. Evaluation of platelet function by PFA-1002. Clin Chem 1994;40:1827–8.
   Web of Science ®Google Scholar
• Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21(Suppl. 2):21–.
   Google Scholar
• Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195–202.
   PubMed Web of Science ®Google Scholar
• Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63–6.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175–8.
   PubMed Web of Science ®Google Scholar
• Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003;34:849–54.
   PubMed Web of Science ®Google Scholar
• Moneta GL, Edwards JM, Chitwood RW, Taylor LM, Jr, Lee RW, Cummings CA, et al. Correlation of North American Symptomatic Carotid Endarterectomy Trial (NASCET) angiographic definition of 70% to 99% internal carotid artery stenosis with duplex scanning. J Vasc Surg 1993;17:152–7.
   PubMed Web of Science ®Google Scholar
• Whisnant JP, Basford JR, Bernstein EF, Cooper ES, Dyken ML, Easton JD, et al. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990;21:637–76.
   Google Scholar
• Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982;32:871–6.
   PubMed Web of Science ®Google Scholar
• Inzitari D, Eliasziw M, Sharpe BL, Fox AJ, Barnett HJ. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. Neurology 2000;54:660–6.
   PubMed Web of Science ®Google Scholar
• Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 1997;77:1104–8.
   PubMed Web of Science ®Google Scholar
• Sukhu K, Martin PG, Cross L, Keeling DM, Giangrande PL. Evaluation of the von Willebrand factor antigen (vWF-Ag) assay using an immuno-turbidimetric method (STA Liatest vWF) automated on the MDA 180 coagulometer. Clin Lab Haematol 2000;22:29–32.
   PubMedGoogle Scholar
• Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963;168:178–95.
   PubMed Web of Science ®Google Scholar
• Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 2000;84:93–7.
   PubMed Web of Science ®Google Scholar
• von Pape KW, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 2000;98:295–9.
   PubMed Web of Science ®Google Scholar
• Feuring M, Haseroth K, Janson CP, Falkenstein E, Schmidt BM, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). Int J Clin Pharmacol Ther 1999;37:584–8.
   PubMed Web of Science ®Google Scholar
• Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997;87:159–64.
   PubMed Web of Science ®Google Scholar
• McCabe DJ, Harrison P, Machin SJ, Watt H, Brown MM. Measurement of the antiplatelet effects of aspirin in cerebro- vascular disease. Stroke 2004;35:e146–7.
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961–5.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Gum PA, Kottke-Marchant K. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease-Reply. J Am Coll Cardiol 2003;42:1336–7.
   PubMed Web of Science ®Google Scholar
• Jilma B. Therapeutic failure or resistance to aspirin. J Am Coll Cardiol 2004;43:1332–3.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001;345:433–42.
   PubMed Web of Science ®Google Scholar
• Chamorro A, Escolar G, Revilla M, Obach V, Vila N, Reverter JC, et al. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. J Neurol Sci 1999;171:110–4.
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316–21.
   PubMed Web of Science ®Google Scholar
• International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569–81.
   Google Scholar
• CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641–9.
   PubMed Web of Science ®Google Scholar
• Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
   PubMed Web of Science ®Google Scholar
• Weber AA, Przytulski B, Schumacher M, Zimmermann N, Gams E, Hohlfeld T, et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclo- oxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002;117:424–6.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999;50:661–7.
   PubMed Web of Science ®Google Scholar
• Reiter R, Resch U, Sinzinger H. Do human platelets express COX-2? Prostaglandins Leukot Essent Fatty Acids 2001;64:299–305.
   PubMed Web of Science ®Google Scholar
• Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634–9.
   PubMed Web of Science ®Google Scholar
• Schro¨r K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349–56.
   PubMed Web of Science ®Google Scholar
• Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004;124:80–5.
   PubMed Web of Science ®Google Scholar
• Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000;111:1250–2.
   PubMed Web of Science ®Google Scholar
• Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999;93:3583–6.
   PubMed Web of Science ®Google Scholar
• Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet 1998;351:1253.
   PubMed Web of Science ®Google Scholar
• Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW. Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype. Stroke 1998;29:2118–24.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989;20:983–9.
   PubMed Web of Science ®Google Scholar
• Robless PA, Tegos TJ, Okonko D, Mansfield AO, Nicolaides AN, Mikhailidis DP, et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 2002;13:231–9.
   PubMed Web of Science ®Google Scholar